文献速递免疫规划传染病防控与疫情报告

日本11个大城市儿童和青少年COVID-19疫苗有效性和保护持续时间:一项回顾性队列研究

COVID-19 vaccine effectiveness and duration of protection among children and adolescents: A retrospective cohort study in 11 large cities in Japan.
PubMed 文献 · Vaccine · 2025-08-27

该研究基于日本11个城市5-17岁居民的SARS-CoV-2监测记录和疫苗接种登记,采用回顾性队列设计,估计COVID-19疫苗对Omicron感染和重症的保护效果及持续时间。共纳入1,908,012条记录,结果显示单价疫苗对Omicron感染的保护有限且快速衰减,但重症保护为中等水平,二价疫苗加强后重症保护更高。

要点

  • 12-17岁基础免疫对Omicron BA.5感染效果2%(95%CI 0-3%),中位接种后9.6个月。
  • 单价和二价第一剂加强针对Omicron BA.5感染效果分别为39%(38-40%)和41%(39-44%)。
  • 对Omicron BA.5重症,基础免疫、单价加强、二价加强效果分别为49%(35-60%)、54%(39-65%)、73%(46-87%)。

核心结论

  • 单价疫苗对Omicron感染的保护有限,部分原因是疫苗诱导免疫快速衰减;对重症的保护为中等,使用二价疫苗时更高;结果支持更新疫苗接种的重要性。

研究设计与样本

  • 回顾性队列研究,纳入日本11个城市5-17岁居民,结合国家SARS-CoV-2监测记录和疫苗接种登记,共1,908,012条记录,采用Cox比例风险回归分析。

主要发现

  • 12-17岁人群基础免疫、单价第一剂加强、二价第一剂加强针对Omicron BA.5感染的效果分别为2%(95%CI 0-3%)(接种后中位9.6个月)、39%(38-40%)、41%(39-44%)。
  • 12-17岁人群对Omicron BA.5重症感染的效果分别为49%(35-60%)、54%(39-65%)、73%(46-87%)。
  • 5-11岁儿童结果与12-17岁相似;混合免疫保护估计为83-97%。
  • 疫苗诱导保护在基础免疫接种后10个月衰减至接近0%,但对重症的保护持续时间更长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: COVID-19 vaccination for children has been debatable. Compiling scientific evidence on vaccine safety and effectiveness was indispensable for the effective vaccine strategy. This study aimed to estimate the effectiveness and protection duration of the COVID-19 vaccine among children and adolescents in Japan. MATERIAL AND METHODS: A retrospective cohort study was conducted targeting residents aged 5-17 years in 11 cities in Japan. Combining the national SARS-CoV-2 surveillance record and vaccination registry, Cox proportional hazard regression analyses were performed to estimate the effectiveness of the original monovalent vaccine against Omicron infection compared with unvaccinated. The duration of protection was also estimated. FINDINGS: A total of 1,908,012 records were included. The effectiveness of primary series vaccination, the monovalent and bivalent first booster dose vaccination against any infection with Omicron BA.5 was 2 % (95 % CI: 0-3 %) (median 9.6 months after vaccination), 39 % (38-40 %), and 41 % (39-44 %) among those aged 12-17 years, respectively. The effectiveness against severe infection with the Omicron BA.5 was 49 % (35-60 %), 54 % (39-65 %), and 73 % (46-87 %), respectively. The result was similar for children aged 5-11 years. The protection of hybrid immunity was estimated at 83-97 %. The vaccine-derived protection waned to nearly 0 % at ten months after primary series vaccination; however, the protection against severe infection persists more than that. DISCUSSION: The monovalent vaccine's protection against Omicron infections was limited, partly due to the rapid waning of vaccine-derived immunity. The protection against severe diseases was moderate, especially when the bivalent vaccine was used. The results reassure the importance of updated vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kitamura N, Tomo Y, Okuyama M, et al. COVID-19 vaccine effectiveness and duration of protection among children and adolescents: A retrospective cohort study in 11 large cities in Japan. Vaccine. 2025. PMID: 40876144. doi:10.1016/j.vaccine.2025.127656

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。